FDA confirms a diagnostic method for Medibio’s final depression validation trial

May 19, 2022 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Medibio (ASX:MEB) has announced that a DSM-V 1 diagnosis will be included as a primary comparator for the purposes of assessing the efficacy of its depression algorithms, MEB-001. …

Subscribe now to continue reading.

Latest Video

Georgia Forrest

Taylor confirms Anne Ruston will retain health portfolio in opposition reshuffle
February 17, 2026 - Latest News
PhRMA targets the PBS, urges 'Priority Watch List' inclusion over policy failings
February 17, 2026 - Latest News
Minister confirms PBS listing for new cystic fibrosis therapy and funded access to other medicines
February 16, 2026 - Latest News
'It’s the first time in over 30 years that a new way of administering adrenaline has been approved in Australia'
February 16, 2026 - Latest News
Life sciences sector unites to advance women’s leadership at landmark 2026 events
February 16, 2026 - Latest News

FDA confirms a diagnostic method for Medibio’s final depression validation trial

This is a preview of subscriber content

Latest Video

Most Read

Taylor confirms Anne Ruston will retain health portfolio in opposition reshuffle

PhRMA targets the PBS, urges 'Priority Watch List' inclusion over policy failings

Minister confirms PBS listing for new cystic fibrosis therapy and funded access to other medicines

'It’s the first time in over 30 years that a new way of administering adrenaline has been approved in Australia'

Life sciences sector unites to advance women’s leadership at landmark 2026 events

New Stories

Telix files for European approval of brain cancer imaging candidate TLX101-Px

IDT signals turnaround as revenue rises and losses narrow under strategic reset

Nyrada advances lead candidate into mid-stage trial as momentum builds across programs

Novo Nordisk backs community-led initiative that aims to transform life for Logan’s children

CSL and Lilly strike strategic deal to advance promising anti-inflammatory therapy

Targeted blood cancer treatments proposed for funding in New Zealand

Percheron targets next wave of immunotherapy with novel VISTA checkpoint candidate

Sign In

FDA confirms a diagnostic method for Medibio’s final depression validation trial

This is a preview of subscriber content

Latest Video

Most Read

Taylor confirms Anne Ruston will retain health portfolio in opposition reshuffle

PhRMA targets the PBS, urges 'Priority Watch List' inclusion over policy failings

Minister confirms PBS listing for new cystic fibrosis therapy and funded access to other medicines

'It’s the first time in over 30 years that a new way of administering adrenaline has been approved in Australia'

Life sciences sector unites to advance women’s leadership at landmark 2026 events

Follow Us

New Stories

Telix files for European approval of brain cancer imaging candidate TLX101-Px

IDT signals turnaround as revenue rises and losses narrow under strategic reset

Nyrada advances lead candidate into mid-stage trial as momentum builds across programs

Novo Nordisk backs community-led initiative that aims to transform life for Logan’s children

CSL and Lilly strike strategic deal to advance promising anti-inflammatory therapy

Targeted blood cancer treatments proposed for funding in New Zealand

Percheron targets next wave of immunotherapy with novel VISTA checkpoint candidate